Abbvie

ABBV

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding

In their latest 13F (Q3 2026)

See who

Value held

$34.0m

Combined value at quarter end

Last quarter

0 bought

5 sold or trimmed

Price at Q3 ’26 end

$261.59

+4.0% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

-10.0%Q4 ’24

+17.9%Q1 ’25

-11.4%Q2 ’25

+24.7%Q3 ’25

-1.3%Q4 ’25

-4.8%Q1 ’26

+15.7%Q2 ’26

+4.0%Q3 ’26

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

7Q4 ’23

7Q1 ’24

7Q2 ’24

6Q3 ’24

6Q4 ’24

6Q1 ’25

7Q2 ’25

7Q3 ’25

7Q4 ’25

7Q1 ’26

7Q2 ’26

1Q3 ’26

Counts the managers on this site whose 13F for that quarter includes Abbvie.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Abbvie

Matrix Asset Advisors	0.7%$8.9m	$8.9m	Trimmed -13%	27 qtrs
Mairs & Power	0.1%$11.2m	$11.2m	Trimmed -1.4%	53 qtrs
Jensen Investment Management	0.1%$2.8m	$2.8m	Trimmed -0.7%	53 qtrs
Horizon Kinetics	0.1%$4.8m	$4.8m	Trimmed -1.7%	30 qtrs
Gardner Russo & Quinn	0.0%$3.1m	$3.1m	Unchanged	53 qtrs
Dodge & Cox	0.0%$2.6m	$2.6m	Unchanged	53 qtrs
Harris Associates (Oakmark)	0.0%$609k	$609k	Trimmed -9.8%	5 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works

From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.

Sort by

Insider purchases and sales of Abbvie
		Bought or sold				Filing
14 Aug 2026	Donoghoe NicholasEVP, CHIEF BUS/STRAT OFFICER	▼ Sold	32,710	$250.00	$8.2m	Form 4

About the company

Sector: Health care · Pharmaceutical Preparations
Incorporated in: Delaware
Financial year ends: 31 December
Shares outstanding: 1.77bn at 27 Jul 2026
SEC filings: Annual reports and other filings on EDGAR

Revenue and profit

$19bn2013

$23bn2015

$28bn2017

$33bn2019

$56bn2021

$54bn2023

$61bn2025

Abbvie revenue and net income by year
Year	Revenue	Net income
2025	$61bn	$4.2bn
2024	$56bn	$4.3bn
2023	$54bn	$4.9bn
2022	$58bn	$12bn
2021	$56bn	$12bn
2020	$46bn	$4.6bn
2019	$33bn	$7.9bn
2018	$33bn	$5.7bn
2017	$28bn	$5.3bn
2016	$26bn	$6.0bn
2015	$23bn	$5.1bn
2014	$20bn	$1.8bn
2013	$19bn	–

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.